| 摘要 |
<p>The present invention is concerned with a method for diagnosing cancer in a subject, comprising the steps of: (a) determining in a sample of said subject the methylation status of at least one CpG site located in the promoter region of the HYAL2 gene; and (b) comparing said methylation status with a reference, whereby cancer is to be diagnosed. The present invention further relates to a method for diagnosing breast cancer in a subject, comprising the steps of: (a) determining in a sample of a subject suspected to suffer from said cancer the amount of a gene product of the HYAL2 gene; and (b) comparing said amount with a reference, whereby breast cancer is to be diagnosed. The present invention also is concerned with a device for diagnosing cancer, comprising an analyzing comprising a detection agent for determining the methylation status of at least one of the CpG sites of the present invention in a sample of a subject, or comprising a detection agent for determining the amount of a HYAL2 gene product in a sample of a subject suspected to suffer from breast cancer, and an evaluation unit comprising a data processor having tangibly embedded an algorithm for carrying out a comparison of the amount determined by the analyzing unit with a stored reference and which is capable of generating an output file containing a diagnosis established based on the said comparison. The present invention also is concerned with a kit for carrying out a method of the present invention and with a method for therapy monitoring in a subject being treated against cancer, comprising the steps of (a) obtaining a first and a second sample from a subject, wherein the first sample is obtained at a time point before the second sample, (b) determining in said first and second sample the methylation status of at least one of the CpG sites of the present invention and (c) comparing the methylation status of said first sample to the methylation status of said second sample, thereby monitoring therapy in said subject.</p> |
